How long is the Arm of “Big Pharma”?

on .

European Parliament, Brussels, Belgium 9.1.2018 – Report by Lauren Tuchman, ANME e.V.

This event at the European Parliament involved the European Medicines Agency (EMA) and was co-hosted by WEMOS (an independent civil society organization based in the Netherlands, whose aim is to improve public health worldwide)...

One intent behind this event was to discuss and understand how the European Medicines Agency (EMA) tackles the idea of transparency, and how the EMA is addressing and minimizing ‘conflicts of interest’. An additional focus was on a discussion of EMA’s openness/willingness to work toward greater attention, time, and allocation of resources to the idea of ‘added therapeutic value.’ This added therapeutic value could be applied to new medicines and independent clinical research as a precursor to decisions made on marketing authorization and acceptance of new pharmaceuticals; added therapeutic value could also aid in assessing, monitoring, enforcing safety, standardization, and accountability for those pharmaceuticals that are already approved and on the market.

Read more in the PDFdownload report

Game Changers for Better and Affordable Medicines for Europe

on .

Universal Access & Affordable Medicines Forum of the European Public Health Alliance, organized by the European Public Health Alliance (epha) under the auspices of the Belgian Ministry of Health 21.11. 2017

By Lauren Tuchman, ANME

This was a well-attended event filled with varying participants from a multitude of organizations. The atmosphere was lively, questions were raised, and the panels throughout the days were diverse, interactive, and the members actively engaged with the attendees. In the opening remarks from Yannis Nastis, (Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance [EPHA]), one point was made that was reiterated by many of the panelists of the day: Access to medicine is no longer just a topic and concern for the Ministry of Health; it is important that the Ministry of Finance become more involved and address public concerns.

“Science-Innovation-Policies”

on .

Report from the 9th World Health Summit 2017 in Berlin, 15th-17th of October

A political update: What’s going on in mainstream Health Policies?

By Nora Laubstein

About 2000 participants attended the three day World Health Summit (WHS) in Berlin under the patronage of Angela Merkel, Emmanuel Macron and German Health Minister Herman Gröhe. The presidency for this year was held by Helene Boisjoly, University of Montreal and WHS-founding President Detlev Ganten, Charite-University. Both are partners of the M8-Alliance, a 2009 founded network of 20 global Academic Health Centers, Universities and National Academies.

Science as a battle: The European Academies Science Advisory Council /EASAC attacks all Homeopathy!

on .

Homeopathic products and practices: assessing the evidence and ensuring consistency in regulating medical claims in the EU” - full report under: http:/www.easac.eu/↗

Please read here the statements of the Homeopathy Reseach Institute/ HRI: https://www.hri-research.org/↗

Bundesverband Pharmazeutischer Industrie/BPI: http://www.bpi.de/↗

and our partner ECHAMP:

ECHAMP is the European Coalition on Homeopathic & Anthroposophic Medicinal Products. It works to develop the industry for these medicinal products so as to ensure availability of both medicines for self-medication and medicines recommended by prescribers. It advocates in favour of an appropriate regulatory environment for these products in the EU.

EFSA Press Release: Bee groups embrace new EU partnership

on .

Beekeepers, scientists, policy-makers and other relevant parties are to set up a European bee partnership that could transform the way bee health is assessed in the EU – Brussels-2017-26th of June.

Comment by Dr. Friedrich Hainbuch, ANME:

As a participant of group TWO I can only speak for this group. In principle, I can say that many delegates and representatives of various EU institutions were involved. Also many representatives of the agrochemical groups and a few scientists attended.
I missed critical and rather skeptical scientists, such as Thomas Seeley, Randolf Menzel, Prof. Tautz, Dr. Safer, Dr. Alexandra Henrion-Claude or G.-E. SérTalini.

In this spectrum research and industrial interests were located, on one side:
The first EU-wide field-study which documents bee-damaging by neonicotinoids, "The degradation rate of thiamethoxam in European field studies"  and on the other side a contradictory study, commissioned by BAYER industries, which showed that Imidacloprid and other neonicotinoids were absolutely non-toxic for bees.

EPO clarifies practice in the area of plant and animal patents

on .

Press release, The Hague / Munich, 29 June 2017

On a proposal of the European Patent Office its Administrative Council took a decision to amend the relevant Regulations in order to exclude from patentability plants and animals exclusively obtained by an essentially biological breeding process.

Press release

Complementary medicine in Switzerland now a mandatory health insurance service

on .

Press release of 16 June 2017

The Swiss Federal Government announces that specific medical services using complementary med- icine are to be covered by mandatory health insurance (basic insurance). The Swiss Umbrella Association for Complementary Medicine and the Union of Associations of Swiss Physicians for Comple-mentary Medicine welcome this decision. It implements one of the key demands of the constitutional referendum held on 17 May 2009. With this decision, the Swiss Federal Council is acknowledging that complementary medicine in Switzerland meets statutory regulations when it comes to effectiveness, guaranteeing high quality and safety.

 Press release 

EU Health Award for NGOs 2016

on .

In 2016, the European Commission’s EU Health Award recognises and rewards the efforts and achievements of European NGOs towards reducing the threat to human health from antimicrobial resistance. Antimicrobial Resistance (AMR) is one of the most challenging threats to human health. Each year, drug resistant infections result in an estimated 25,000 deaths and 1.5 billion euros in healthcare costs and productivity losses in the EU. 

For the winners of EU Health Award look here ↗

The summary report of the winner BEUC/The European Consumer Organisation is linked here ↗